DE60023943D1 - Antisense oligonucleotides zur inhibition der expression von type i procollagen - Google Patents

Antisense oligonucleotides zur inhibition der expression von type i procollagen

Info

Publication number
DE60023943D1
DE60023943D1 DE60023943T DE60023943T DE60023943D1 DE 60023943 D1 DE60023943 D1 DE 60023943D1 DE 60023943 T DE60023943 T DE 60023943T DE 60023943 T DE60023943 T DE 60023943T DE 60023943 D1 DE60023943 D1 DE 60023943D1
Authority
DE
Germany
Prior art keywords
expression
procollagen
inhibition
type
antisense oligonucleotides
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60023943T
Other languages
English (en)
Other versions
DE60023943T2 (de
Inventor
Rajinder Beri
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
RAHUL KUMAR NATH
Original Assignee
RAHUL KUMAR NATH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by RAHUL KUMAR NATH filed Critical RAHUL KUMAR NATH
Publication of DE60023943D1 publication Critical patent/DE60023943D1/de
Application granted granted Critical
Publication of DE60023943T2 publication Critical patent/DE60023943T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/315—Phosphorothioates

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Dermatology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
DE60023943T 1999-12-15 2000-12-12 Antisense oligonukleotide zur inhibition der expression von typ i prokollagen Expired - Lifetime DE60023943T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB9929487.8A GB9929487D0 (en) 1999-12-15 1999-12-15 Antisense oligonucleotides
GB9929487 1999-12-15
PCT/GB2000/004741 WO2001044455A2 (en) 1999-12-15 2000-12-12 Antisense oligonucleotides for the inhibition of expression of type i procollagen

Publications (2)

Publication Number Publication Date
DE60023943D1 true DE60023943D1 (de) 2005-12-15
DE60023943T2 DE60023943T2 (de) 2006-08-03

Family

ID=10866254

Family Applications (2)

Application Number Title Priority Date Filing Date
DE60040495T Expired - Lifetime DE60040495D1 (de) 1999-12-15 2000-12-12 Antisense Oligonukleotide zur Expressionshemmung des Typ I-Prokollagens
DE60023943T Expired - Lifetime DE60023943T2 (de) 1999-12-15 2000-12-12 Antisense oligonukleotide zur inhibition der expression von typ i prokollagen

Family Applications Before (1)

Application Number Title Priority Date Filing Date
DE60040495T Expired - Lifetime DE60040495D1 (de) 1999-12-15 2000-12-12 Antisense Oligonukleotide zur Expressionshemmung des Typ I-Prokollagens

Country Status (17)

Country Link
US (1) US7173122B2 (de)
EP (3) EP2025752A3 (de)
JP (1) JP2003516752A (de)
KR (1) KR20020064936A (de)
CN (1) CN1423695A (de)
AT (2) ATE309338T1 (de)
AU (1) AU2529701A (de)
BR (1) BR0016347A (de)
CA (1) CA2390674A1 (de)
DE (2) DE60040495D1 (de)
GB (1) GB9929487D0 (de)
IL (1) IL149640A0 (de)
MX (1) MXPA02005871A (de)
NO (1) NO20022799L (de)
NZ (1) NZ519008A (de)
WO (1) WO2001044455A2 (de)
ZA (1) ZA200203878B (de)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7396823B2 (en) * 1999-12-15 2008-07-08 Nath Rahul K Therapy inhalation involving antisense oligonucleotides for treating idiopathic pulmonary fibrosis
CN111378657B (zh) * 2018-12-28 2024-03-15 苏州瑞博生物技术股份有限公司 抑制COL1A1基因表达的siRNA、含有该siRNA的药物组合物及其用途

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6265157B1 (en) * 1991-12-03 2001-07-24 Allegheny University Of The Health Sciences Compositions and methods for detecting altered COL1A1 gene sequences
WO1993011149A1 (en) * 1991-12-03 1993-06-10 Thomas Jefferson University Methods of detecting a genetic predisposition for osteoporosis
JPH08503366A (ja) * 1992-11-09 1996-04-16 トーマス・ジェファーソン・ユニバーシティ コラーゲンの突然変異および野生型遺伝子の発現を阻害するアンチセンスオリゴヌクレオチド
CA2159195A1 (en) 1993-03-26 1994-10-13 Darwin J. Prockop Use of a col 1a1 mini-gene construct to inhibit collagen synthesis
EP0739898B1 (de) * 1995-03-13 2001-09-26 Aventis Pharma Deutschland GmbH Phosphonomonoesternnukleinsäuren, Verfahren zu ihrer Herstellung und ihre Verwendung
DE19508923A1 (de) * 1995-03-13 1996-09-19 Hoechst Ag Phosphonomonoesternukleinsäuren, Verfahren zu ihrer Herstellung und ihre Verwendung
EP0736608A1 (de) * 1995-04-08 1996-10-09 Roche Diagnostics GmbH Verfahren zur spezifischen Vervielfältigung und zum Nachweis von DNA bzw. RNA
EP0856579A1 (de) 1997-01-31 1998-08-05 BIOGNOSTIK GESELLSCHAFT FÜR BIOMOLEKULARE DIAGNOSTIK mbH Ein Verfahren zur Zubereitung von Antisense Oligonukleotiden
US6238921B1 (en) * 1998-03-26 2001-05-29 Isis Pharmaceuticals, Inc. Antisense oligonucleotide modulation of human mdm2 expression
US6007995A (en) * 1998-06-26 1999-12-28 Isis Pharmaceuticals Inc. Antisense inhibition of TNFR1 expression
CA2399371A1 (en) * 1999-11-12 2001-05-17 Fibrogen, Inc. Animal collagens and gelatins

Also Published As

Publication number Publication date
ATE309338T1 (de) 2005-11-15
AU2529701A (en) 2001-06-25
EP1698695A3 (de) 2007-02-14
NO20022799D0 (no) 2002-06-12
IL149640A0 (en) 2002-11-10
EP1698695A2 (de) 2006-09-06
KR20020064936A (ko) 2002-08-10
BR0016347A (pt) 2002-09-10
NO20022799L (no) 2002-06-12
CA2390674A1 (en) 2001-06-21
WO2001044455A3 (en) 2002-01-10
WO2001044455A2 (en) 2001-06-21
CN1423695A (zh) 2003-06-11
ATE410510T1 (de) 2008-10-15
DE60023943T2 (de) 2006-08-03
US7173122B2 (en) 2007-02-06
NZ519008A (en) 2004-04-30
EP2025752A3 (de) 2009-08-12
US20030105050A1 (en) 2003-06-05
EP2025752A2 (de) 2009-02-18
ZA200203878B (en) 2003-08-15
EP1244781A2 (de) 2002-10-02
DE60040495D1 (de) 2008-11-20
EP1698695B1 (de) 2008-10-08
MXPA02005871A (es) 2002-10-23
GB9929487D0 (en) 2000-02-09
EP1244781B1 (de) 2005-11-09
JP2003516752A (ja) 2003-05-20

Similar Documents

Publication Publication Date Title
CY1116385T1 (el) Αντινοηματικη διαμορφωση της εκφρασης της απολιποπρωτεινης β
DE69431164T2 (de) Gegenläufige oligonukleotide mit hemmender wirkung auf tumorbildung
ATE273718T1 (de) Methoxyethoxy-oligonukleotide zur regulierung der proteinkinase c expression
DE50214715D1 (de) Synthetische doppelsträngige oligonucleotide zur gezielten hemmung der genexpression
ATE428780T1 (de) Verfahren zur zubereitung von antisense oligonukleotiden
ATE442152T1 (de) Antisense-entwurf
DK0920498T3 (da) Hamster EF-1alfa transskriptionelt, regulatorisk DNA
FI964792A (fi) raf-geenin ilmentymisen muuttaminen antisense-oligonukleotideillä
ATE257128T1 (de) Schwefelfreies lignin und dessen derivate zur herabsetzung der bildung von schleim und ablagerungen in industriellen anlagen
ATE450610T1 (de) Pflanzliche defensine
ATE309338T1 (de) Antisense oligonucleotides zur inhibition der expression von type i procollagen
DE1206274T1 (de) Verwendung von interleukin-18-inhibitoren zur hemmung von tumormetastasierung
ATE214708T1 (de) Kationische mittel zur transfektion von nukleinsäuren
ATE369422T1 (de) Antisense-oligonukleotid zur hemmung der melanom- inhibierenden aktivität (mia)
DE60137721D1 (de) Inhibitoren von lyn-verbundener signaltransduktion (last) und deren verwendung zur behandlung von prostatakrebs
SE0302965D0 (sv) Hämmare av DNA-Metyltransferasisoformer
DE50105650D1 (de) Verwendung von niedermolekularen heparin zur behandlung von osteoarthrose
TW200502244A (en) Expression of zebrafish bone morphogenetic protein 4
ATE366320T1 (de) Verfahren zur erhöhung der genexpression der transfizierten genen
CY1114199T1 (el) Αντιπληροφοριακη διαμορφωση της εκφρασης της απολιποπρωτεϊνης β
ATA197498A (de) Verfahren zur oxidation von methyl-, methylen- oder methingruppen enthaltenden substraten
ATA112799A (de) Verfahren zur oxidation von methyl-, methylen- oder methingruppen enthaltenden substraten

Legal Events

Date Code Title Description
8364 No opposition during term of opposition